In silico drug-gene interaction analysis has suggested several novel potential therapies, including the JAK inhibitor ruxolitinib, the BTK inhibitor (BTKi) ibrutinib or interleukin 2 (IL-2) in addition to currently used drugs according to the EUGOGO clinical guidelines (prednisone/prednisolone, rituximab, mycophenolic acid, and cyclosporine) and agents used in the treatment of other autoimmune diseases (cyclophosphamide, indomethacin, and methotrexate). Here, BTK is linked to autoimmune disease.